SEC FORM 3

Please wait

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gunn Justin Frederick

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2026

3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	12,191⁽¹⁾⁽²⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to buy)	⁽³⁾	08/01/2034	Common Stock	25,000	$37.94	D
Stock option (right to buy)	⁽⁴⁾	02/28/2035	Common Stock	25,000	$60.58	D
Stock option (right to buy)	⁽⁵⁾	02/27/2036	Common Stock	13,438	$35.7	D
Stock option (right to buy)	⁽⁶⁾	02/27/2036	Common Stock	8,959	$35.7	D

Explanation of Responses:

1. Includes 141 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 316 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 405 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 103 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. Includes 6,000 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. The shares underlying the restricted stock unit will vest in equal installments on each quarterly anniversary of September 1, 2026 over a four-year period provided the Reporting Person satisfies certain requirements.

3. There were originally 50,000 shares subject to the stock option and an aggregate of 25,000 shares have been previously exercised. The shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on August 1, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on August 1, 2028, subject to the Reporting Person's continued service.

4. Exercisable ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

5. There were originally 15,000 shares subject to the stock option and an aggregate of 1,562 shares have been previously exercised. The shares subject to the stock option vested and became exercisable ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

6. There were originally 10,000 shares subject to the stock option and an aggregate of 1,041 shares have been previously exercised. The shares subject to the stock option vested and became exercisable ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

President, Corcept Endocrinology Exhibit 24 - Power of Attorney

	By: /s/ Joseph Douglas Lyon, as attorney-in-fact for Justin Gunn	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.